Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

No Fast Track For Lecanemab In EU Disappoints Eisai

Pan-EU Approval Could Come In March 2024, Says Company

19 Jan 2023

• By Andrew McConaghie

EMA — Lecanemab could be approved in the European Union by March 2024 - well over a year after the US accelerated approval. • Source: Shutterstock

Related Content

Biogen Pulls EU Filing For Aduhelm But Stands By Alzheimer’s Drug

22 Apr 2022

Is Lecanemab Plus t-PA A Deadly Combination? One Case Study May Shed Light

05 Jan 2023

Eisai Files Alzheimer’s Drug Lecanemab In Europe But Will EMA Grant Fast Track?

13 Jan 2023

Eisai’s Lecanemab: US FDA Showed Flexibility On Clinical Endpoint Results, Safety Database Size

12 Jan 2023

Closing The Books On Aduhelm: Congressional Report Leaves US FDA To Move Forward

11 Jan 2023

Related Companies

Eisai Co., Ltd.

Biogen, Inc.

Additional Topics

Clinical Trials Drug Review Regulation Neurology BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.